A structured evaluation of your Quality Management System against ISO 9001:2015 and GxP regulatory requirements — identifying gaps, quantifying compliance risk and producing a prioritised remediation roadmap.
In pharmaceutical, chemical and regulated manufacturing environments, a Quality Management System is both a regulatory obligation and a direct operational lever. Yet most QMS programmes in asset-intensive organisations were assembled over time — accumulating procedures, forms and approvals that satisfy inspectors but do not connect quality events to the asset conditions and maintenance practices that generate them.
Non-conformances recur. CAPAs close on paper but not in practice. Equipment-related quality failures repeat because the QMS and the maintenance programme exist in parallel rather than as an integrated system.
Optimal's QMS Gap Assessment evaluates your quality management system against ISO 9001:2015 and applicable GxP requirements — and critically, examines how quality processes integrate with asset management, maintenance and reliability practice across the facility.
The assessment scope is configured to the regulatory environment of your site. For pharmaceutical manufacturers, GMP alignment and GxP documentation requirements are assessed alongside the core ISO 9001 clauses.
The international Quality Management System standard — 10-clause structure covering context, leadership, planning, support, operations, performance evaluation and improvement. Assessed across all clauses with maturity scoring and gap identification.
Good Manufacturing Practice requirements applicable to pharmaceutical, biotechnology and medical device manufacturers — including equipment qualification, change control, deviation management and documentation standards aligned to EU GMP Annex, ICH Q10 and WHO guidelines.
Where the client operates under or targets ISO 55001 certification, the QMS assessment maps quality system requirements to the asset management system — identifying shared governance structures, integrated auditing opportunities and overlapping documentation.
The assessment reviews whether quality risk management processes reflect ICH Q9 methodology — including FMEA, HACCP and other risk tools used to prioritise quality controls across manufacturing and asset operations.
Data integrity assessed across quality records, equipment logs, calibration data and maintenance documentation — evaluating Attributability, Legibility, Contemporaneousness, Originality and Accuracy requirements applicable to GxP-regulated data sources.
For sites managing environmental management systems alongside quality, the assessment can extend to review the QMS-EMS interface — identifying integration opportunities and shared documentation structures that reduce overall audit burden.
The assessment follows a structured five-phase methodology — combining document review, process walkthroughs and personnel interviews with direct observation of quality activities in the facility. Each ISO 9001 clause is scored on a five-level maturity scale, producing a clause-by-clause gap register and remediation roadmap sequenced by regulatory risk.
The output is not a compliance checklist. It is a management tool — connecting quality system weaknesses to the operational, maintenance and asset management practices that drive quality failures in regulated manufacturing environments.
A secondary pharmaceutical manufacturer operating under both SAHPRA and WHO GMP requirements engaged Optimal following a regulatory inspection that identified systemic weaknesses in equipment-related quality records, change control and the maintenance–quality interface. The QMS Gap Assessment identified gaps across ISO 9001 and GMP requirements — the majority relating to inadequate control of equipment qualification status, poor calibration documentation and a CAPA system closing findings without verified effectiveness reviews. The remediation roadmap was implemented with Optimal providing programme management support through the first full CAPA closure cycle.
Optimal's QMS Gap Assessments are conducted by quality and asset management practitioners with direct experience of pharmaceutical and regulated manufacturing environments — scoped to your regulatory context, whether you are preparing for re-inspection, working toward ISO 9001 certification or addressing findings from an internal audit programme.
Request a scoping call